The board has considered the option of spin-off of the injectable business to a wholly owned subsidiary as a going concern, in order to strengthen and provide focused growth to the injectable business and to leverage strategic opportunities.
Meanwhile, Aurobindo Pharma reported a consolidated net profit of Rs 18.6 crore for the quarter ended June 30, 2013 (Q1) against a net loss of Rs 129 crore in the corresponding quarter last fiscal.
FOR COMPLETE REPORT READ: Aurobindo Pharma surges on strong Q1 results